Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Deals
Biotech
Galecto buys leukemia drug, drops bone cancer asset in pivot
A year after the failure of a fibrosis drug sent Galecto on a search for salvation, the biotech has decided to go all-in on oncology and liver disease
James Waldron
Oct 7, 2024 10:07am
AstraZeneca pays CSPC $100M for preclinical heart disease drug
Oct 7, 2024 6:12am
Psyence walks away from acquisition of fellow psilocybin biotech
Oct 7, 2024 5:16am
Editas cashes in on Vertex Cas9 licensing agreement for $57M
Oct 4, 2024 5:06am
Lundbeck taps Charles River for AI-enabled neuro drug discovery
Oct 2, 2024 9:21am
BioMarin goes CAMPing, striking RNA deal with biotech
Oct 1, 2024 9:55am
